Imaging synaptic density in the living human brain
The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo imaging of synaptic density is now possible using PET and [ 11 C]UCB-J - a radioligand that binds to the synaptic vesicle protein 2A (SV2A) 41 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [41]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
In the citing paper
“there was also good correlation between SV2A and the “gold standard” pre-synaptic density marker synaptophysin in western blot and confocal microscopy experiments”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“Thus, it was decided that SV2A can be used as an alternative to synaptophysin for quantification of synapse density”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“quantification of radiotracer binding to SV2A does correlate with measures of synaptic vesicle number [8,9,69,70] and expression of other pre-synaptic proteins classically used in postmortem and in vitro work (e.g., synaptophysin, synapsin).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · cited 2×
“2 × 10(14) synapses per liter of brain tissue, as reported for the female human brain (42), and two to five SV2A copies per vesicle (31, 36), it can be estimated that there are 154 to 385 vesicles per synapse.”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11), or schizophrenia (12, 13).”
BackgroundWiedenmann, B., & Franke, W. W. (1985) · Cell · doi:10.1016/s0092-8674(85)80082-9 · Cited by 1,428 · cited 1×
“SYN is themost abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33), because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins.”
BackgroundLoss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
Research works printed but not linked: 1
- 10.1097/01.wcb.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
Cited by
Items 301–400 of 592
Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET
Tuncel, H., Boellaard, R., Coomans, E. M., Hollander-Meeuwsen, M. D., de Vries, E. F. J., Glaudemans, A. W. J. M., Feltes, P. K., García, D. V., Verfaillie, S. C. J., Wolters, E. E., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-021-00874-8 · Cited by 9
“Kinetic analysis (non‐linear regression) Earlier studies have determined that a 1T2k_VB best describes the in vivo kinetics of [11C]UCB-J [9, 10].”
BackgroundResultHusain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M. S., Ahmed, F., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05788-y · Cited by 10
“However, positron emission tomography (PET) imaging radiotracers targeting SV2A are now considered the first-in-class non-invasive method to measure synaptic density in vivo in humans [32].”
BackgroundMethodInfluential[18F]SynVest-1 PET imaging in people with Parkinson’s disease
Martin, S. L., Uribe, C., Desmond, K. L., Narciso, L., Dolman, B., Torres‐Carmona, E., Boileau, I., Graff‐Guerrero, A., Vasdev, N., & Strafella, A. P. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf258 · Cited by 9
Wong, T., Qiu, Z., Notman, B., Tavares, A., Smith, C., & Grant, S. G. N. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.24668.1 · Cited by 10
Preclinical Evaluation of Novel PET Probes for Dementia
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 9
O’Dell, R. S., Higgins‐Chen, A., Gupta, D., Chen, M., Naganawa, M., Toyonaga, T., Lu, Y., Ni, G. S., Chupak, A., Zhao, W., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103457 · Cited by 10
“To assess the spatiotemporal distribution of synaptic density in vivo, [11C]UCB-J, a positron emission tomography (PET) tracer for synaptic vesicle glycoprotein 2A (SV2A) was developed and advanced for human studies (Finnema et al., 2016; Finnema et al., 2018; Nabulsi et al., 2016).”
BackgroundSelf-citationRogeau, A., Boer, A. J., Guedj, É., Sala, A., Sommer, I. E., Veronese, M., van der Weijden-Germann, M., Weehaeghe, D. V., Cecchin, D., Verger, A., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06987-1 · Cited by 11
Positron emission tomography in the COVID-19 pandemic era
Jin, C., Luo, X., Qian, S., Zhang, K., Gao, Y., Zhou, R., Cen, P., Xu, Z., Zhang, H., & Tian, M. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05347-7 · Cited by 9
On the road towards the global analysis of human synapses
Prieto, G. A., & Cotman, C. W. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.217321 · Cited by 9
“SV2A by pharmacological and biochemical assays (Finnema et al., 2016).”
BackgroundMethodInfluentialWillekens, S. M. A., Weehaeghe, D. V., Damme, P. V., & Laere, K. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3587-y · Cited by 10
Salardini, E., O’Dell, R. S., Tchorz, E., Nabulsi, N., Huang, Y. H., Carson, R. E., van Dyck, C. H., & Mecca, A. P. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01739-1 · Cited by 8
“Our previous work using [ 18 F]FPEB and [ 11 C]UCB-J PET showed that both mGluR5 binding and synaptic density are significantly lower in the medial temporal lobe of individuals with AD with largest effect sizes in the hippocampus [13].”
InfluentialSelf-citationSynaptic Density in Multiple Sclerosis: An In Vivo Study Using [ 11 C]UCB-J-PET Imaging
Luoma, A., Matilainen, M., Tuisku, J., Aarnio, R., Nikkilä, T., Laaksonen, S., Koivumäki, M., Honkonen, E., Nylund, M., Wahlroos, S., et al. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200435 · Cited by 10
“12,14 The aims of this study were to examine the density of SV2A in pwMS compared with healthy controls (HCs) in vivo and to explore the relationships between SV2A availability and cognitive disability and other clinical and radiologic characteristics.”
Self-citationDahl, K., Larsson, S., Bonn, P., Wallin, A., Itsenko, O., & Schöll, M. (2022) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4002 · Cited by 9
Advances in PET imaging of ischemic stroke
Orhii, P., Haque, M. E., Fujita, M., & Selvaraj, S. (2023) · Frontiers in Stroke · doi:10.3389/fstro.2022.1093386 · Cited by 9
“SV2A is co-localized with synaptophysin (Finnema et al., 2016), a widely used marker of synaptic density.”
BackgroundSynaptic signaling modeled by functional connectivity predicts metabolic demands of the human brain
Klug, S., Murgaš, M., Godbersen, G. M., Hacker, M., Lanzenberger, R. R., & Hahn, A. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120658 · Cited by 10
“Furthermore, an association was observed with the regional distribution of SV2A, a marker for synaptic density (Carson et al., 2022; Finnema et al., 2016), which also correlates with regional variation of [ 18 F]FDG metabolism (Chen et al., 2021; Yu, 2022), AG (van Aalst et al., 2021) and…”
BackgroundMarkicevic, M., Mandino, F., Toyonaga, T., Cai, Z., Fesharaki‐Zadeh, A., Shen, X., Strittmatter, S. M., & Lake, E. M. R. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2024.0095 · Cited by 8
“68,69 Recent validation studies in humans 61,70 – 73 and nonhuman primates 74,75 include pio-neering work measuring synapse losses in patients with temporal lobe epilepsy, 71 and severe depression.”
ACNP 61st Annual Meeting: Poster Abstracts P1 - P270
(2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01484-1 · Cited by 9
Bærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
“Changes in SV2A availability are proposed as a proxy of synaptic density and plasticity (Holmes, 2019; Holmes et al., 2022; Johansen et al., 2023; Finnema et al., 2016; Chen et al., 2018; Toyonaga et al., 2019; Radhakrishnan et al., 2021; Raval et al., 2021; Nabulsi et al., 2016).”
Chen, B., Zheng, C., Balayeva, T., Toyonaga, T., Wang, X., Tong, J., Mennie, W., Mihailovic, J. M., Coman, D., Hyder, F., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269291 · Cited by 10
“…glycoprotein 2A (SV2A), a 12-transmembrane glycoprotein found in synaptic vesicles of neurons, has emerged as a promising PET imaging target for assessing synaptic density in neurodegenerative conditions, including Alzheimer disease, ischemic stroke ( 18 – 21 ), and traumatic brain injury ( 22 ).”
Self-citationAltered Synaptic Plasticity: Plausible Mechanisms Associated With Viral Infections
Saini, V., Rani, A., Kumar, A., Jha, K., Karnati, S., & Jha, H. C. (2023) · Future Virology · doi:10.2217/fvl-2023-0105 · Cited by 7
Functional Brain Networks to Evaluate Treatment Responses in Parkinson's Disease
Barbero, J., Unadkat, P., Choi, Y. Y., & Eidelberg, D. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01433-w · Cited by 8
On, M. B., Lee, Y.-J., Srouji, L. E., Abdelghany, M., & Yoo, S. J. B. (2024) · Journal of Lightwave Technology · doi:10.1109/jlt.2024.3439336 · Cited by 7
“In a human brain, 100 billion (10 11 ) neurons are interconnected sparsely with each other via 100 trillion (10 14 ) synapses [61].”
First-in-Human PET Imaging of [ 18 F]SDM-4MP3: A Cautionary Tale
Desmond, K. L., Lindberg, A., García, A., Tong, J., Harkness, M. B., Dobrota, E., Smart, K. A., Uribe, C., Meyer, J. H., Houle, S., et al. (2023) · Molecular Imaging · doi:10.1155/2023/8826977 · Cited by 7
“[(18)F]SDM-8 or [(18)F]MNI-1126) is a PET radiopharmaceutical that binds to the synaptic vesicle protein 2A (SV2A) and is considered to be a biomarker of synaptic density [1].”
BackgroundSelf-citationVanderlinden, G., Carron, C. P., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01224-5 · Cited by 7
“11 C-UCB-J shows good pharmacokinetics, quantification of 11 C-UCB-J distribution volume is possible and is an vivo proxy of synaptic density [26, 27].”
BackgroundMeasurement of synaptic density in Down syndrome using PET imaging: a pilot study
DiFilippo, A. H., Jonaitis, E. M., Makuch, R., Piro‐Gambetti, B., Fleming, V., Ennis, G. E., Barnhart, T. E., Engle, J. W., Bendlin, B. B., Johnson, S. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54669-7 · Cited by 8
Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang, X. T., Raval, N. R., O’Dell, R. S., Naganawa, M., Mecca, A. P., Chen, M.-K., van Dyck, C. H., & Carson, R. E. (2024) · Brain Communications · doi:10.1093/braincomms/fcae107 · Cited by 7
“7,11,12 Previously, [ 11 C]UCB-J PET studies reported decreased SV2A binding in medial temporal and neocortical regions in early Alzheimer’s disease compared with cognitively normal (CN) participants.”
BackgroundSelf-citationDifferential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome
Holland, N., Savulich, G., Jones, P. S., Whiteside, D. J., Street, D., Swann, P., Naessens, M., Malpetti, M., Hong, Y. T., Fryer, T. D., et al. (2024) · Movement Disorders · doi:10.1002/mds.29814 · Cited by 7
“We acknowledge that [ 18 F] AV-1451 has high af fi nity for AD-related tau, and low af fi nity for the 4R-tau of CBD. 39 [ 11 C]PiB PET β -Amyloid imaging using [ 11 C]PiB followed Holland et al (2020).”
InfluentialbFGF-Chitosan “brain glue” promotes functional recovery after cortical ischemic stroke
Mu, J., Zou, X., Bao, X., Yang, Z., Hao, P., Duan, H., Zhao, W., Gao, Y., Wu, J., Miao, K., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.12.017 · Cited by 16
“SV2A can be visualized and quantified by PET/CT imaging with the novel SV2A specific radio ligand [ 18 F] SDM-8, which have been widely used as a suitable biomarker for synaptic density in vivo [45].”
Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery
Mercier, J., Provins, L., & Hannestad, J. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12437-0 · Cited by 8
Self-citationThe pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain
Goutal, S., Guillermier, M., Becker, G., Gaudin, M., Bramoullé, Y., Luxen, A., Lemaire, C. F., Plenevaux, A., Salmon, É., Hantraye, P., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00777-8 · Cited by 8
“The demonstration of the colocalization of SV2A with other synaptic markers using [11C]-UCB-J [13], showed the potential of in vivo imaging of the synaptic density using Positron Emission Tomography (PET), and led recently to the development of new [18F]-labelled ligands [9, 14–19].”
MethodScarpa, M., Vallera, E., Ausellé‐Bosch, S., Rocha, F. M., Mercan, B. E., Roy, A., Nordberg, A. K., & Kumar, A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14409 · Cited by 8
eSylites: Synthetic Probes for Visualization and Topographic Mapping of Single Excitatory Synapses
Huhn, C., Ho, S., Schulte, C., Khayenko, V., Hemmen, K., Peulen, T.-O., Wiessler, A.-L., Bothe, S., Bej, A., Talucci, I., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00772 · Cited by 7
Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
Cawthorne, C., Maguire, R. P., Mercier, J., Sciberras, D. G., Serdons, K., Bormans, G. M., Hoon, J. N. J. M. D., Laere, K. V., & Koole, M. J. B. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00384-5 · Cited by 6
“The distribution volume (VT) of [ (11)C]-UCB-J has been correlated with both SV2A and synaptophysin expression level in the primate brain [1].”
Self-citationShatalina, E., Onwordi, E. C., Whitehurst, T., Whittington, A., Mansur, A., Arumuham, A., Statton, B. K., Berry, A., Marques, T. R., Gunn, R. N., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00190 · Cited by 9
“The development of [11C]UCB-J positron emission tomography (PET) provides an in vivo measure of synaptic vesicle protein 2A (SV2A), which is ubiquitously expressed in synaptic terminals ( Finnema et al., 2016, 2018).”
BackgroundMethodDevelopment of Peptide-Based Probes for Molecular Imaging of the Postsynaptic Density in the Brain
Fernandes, E. F. A., Palner, M., Raval, N. R., Jeppesen, T. E., Danková, D., Bærentzen, S. L., Werner, C. D., Eilts, J., Maric, H. M., Doose, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00615 · Cited by 6
Approaches for the discovery of novel positron emission tomography radiotracers for brain imaging
Need, A. B., Kant, N., Jesudason, C. D., & Barth, V. (2017) · Clinical and Translational Imaging · doi:10.1007/s40336-017-0221-3 · Cited by 6
“density [5] and to detect the presence of pathological protein aggregates such as amyloid beta plaques [6] and tau neurofibrillary tangles [7].”
BackgroundPracitto, R., Wilcox, K. C., Lindemann, M., Tong, J., Zheng, C., Li, S., Finnema, S. J., Huang, Y. H., & Cai, Z. (2021) · ACS Omega · doi:10.1021/acsomega.1c02433 · Cited by 6
Self-citationBetter Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 7
Li, A., Yang, B., Naganawa, M., Fontaine, K. M., Toyonaga, T., Carson, R. E., & Tang, J. (2023) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ad0535 · Cited by 5
Self-citationMicrodosing Psychedelics to Restore Synaptic Density in Schizophrenia
Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 8
“This limitation has been overcome by the development of a new PET radioligand [11C] UCB-J, specific for the synaptic vesicle glycoprotein 2A (SV2A) expressed by presynaptic terminals, enabling the assessment of synaptic density in living human brains [29,30].”
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use
Juengling, F. D., Wuest, F. R., Schirrmacher, R., Abele, J. T., Thiel, A., Soucy, J., Camicioli, R. M., & Garibotto, V. (2024) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2024.31 · Cited by 6
Lu, X., Ji, B., Huang, G., & Ding, H. Y. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.04.013 · Cited by 5
“…correlation across all gray matter regions between in vivo [ 11 C]-UCB-J binding and synaptic density, examined by immunochemical analysis, for a gold standard biomarker of synaptophysin, indicating the utility of SV2A-PET imaging for non-invasive quantification of synaptic density [30 , 31] .”
Luo, X.-Y., Jin, C.-T., Chen, H., Niu, J., Yu, C.-C., Dou, X.-F., Wang, J., Wen, J.-J., Zhang, H., Tian, M., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06904-6 · Cited by 5
Neuroimaging Biomarkers in Parkinson’s Disease
Holmes, S. E., & Tinaz, S. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69491-2_21 · Cited by 6
Berckmans, L., Schrauwen, C., Miranda, A., Staelens, S. G., & Bertoglio, D. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07170-w · Cited by 6
Positron Emission Tomography in Autism Spectrum Disorder: Current Status and Future Perspectives
Ryu, J., & Oh, M. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.003 · Cited by 5
Luan, Y., Huang, Q., Wang, J., Guan, Y., Li, B., Franzmeier, N., Xie, F., & Ewers, M. (2025) · Brain · doi:10.1093/brain/awaf425 · Cited by 5
Zheng, C., Toyonaga, T., Chen, B., Nicholson, L., Mennie, W., Liu, M., Spurrier, J. M., DeLuca, K., Strittmatter, S. M., Carson, R. E., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1045644 · Cited by 5
Self-citationHartz, S. M., Goswami, S., Oliver, A. I., Evans, A., Jackson, S., Linnenbringer, E. L., Moulder, K. L., Morris, J. C., & Mozersky, J. T. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-099970 · Cited by 6
Modulation of premotor cortex response to sequence motor learning during escitalopram intake
Molloy, E. N., Mueller, K., Beinhölzl, N., Blöchl, M., Piecha, F. A., Pampel, A., Steele, C. J., Scharrer, U., Zheleva, G., Regenthal, R., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20965161 · Cited by 6
“We cannot, however, identify underlying molecular mechanisms, which require quantitative measures such as MRspectroscopy measures of GABA and glutamate or [(11)C]UCB-J positron emission tomography, a recently developed technique for in vivo imaging of synaptic plasticity.(86,87) In conclusion, this is the first study…”
Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain
Mikkelsen, J. D., Aripaka, S. S., Bascuñana, P., Bankstahl, M., Bankstahl, J. P., & Pazarlar, B. A. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.07.020 · Cited by 5
“Apart from a drug target, SV2A has also recently been proposed to be a convenient biomarker of synaptic density (Finnema et al., 2016; Loscher et al., 2016; Bahri et al., 2017; Becker et al., 2020).”
Asch, R., Naganawa, M., Nabulsi, N., Huan, Y., Esterlis, I., & Carson, R. E. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231200423 · Cited by 5
Self-citationYang, Y., Zheng, C., Chen, B., Hernandez, N. C., Faust, P. L., Cai, Z., Louis, E. D., & Matuskey, D. (2023) · The Cerebellum · doi:10.1007/s12311-023-01611-8 · Cited by 5
Self-citationA New Tool for Clinical Neuroscience—Synaptic Imaging
Mormino, E. C., & Jagust, W. J. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1643 · Cited by 6
Krystal, J. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0760-4 · Cited by 5
First in vivo evaluations of synaptic density alterations in the brain
Esterlis, I., & Holmes, S. E. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01099-y · Cited by 6
“Several groups have now published findings using this novel technology and report quantifications of in vivo alterations in synaptic density including in individuals with epilepsy [1], schizophrenia [2], cannabis use disorder [3], and Alzheimer’s disease [4], in line with some of the previous postmortem findings (dire…”
MethodResultPlasticity markers in the human brain associated with rapid antidepressants
Siegel, J. S., & Nicol, G. E. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01400-7 · Cited by 5
“SV2A can be quantified in vivo using the positron emission tomography (PET)-based radiotracer (11)C-UCB-J [1].”
MethodPlasma growth-associated protein 43 correlates with synaptic loss in Alzheimer’s disease
Lan, G., Li, B., Wang, M., Barve, A., Colin, M., Buée, L., Zhang, L., Jiang, M., Yang, J., Li, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102508 · Cited by 4
Chauca, J. M. N., Sánchez, M., Quintana, N. G., Márquez, K. L. M. D. C., Juarez, B. A. C., Mendoza, N. R., & Díaz, M. A. A. (2026) · Neurology International · doi:10.3390/neurolint18010010 · Cited by 5
“The SV2A tracer [ 11 C]UCB-J provides a direct measure of synaptic density [30,31], whereas FDG-PET reveals metabolic compensation—where stable cognition coexists with elevated glucose metabolism in prefrontal regions despite hippocampal hypometabolism [32–35].”
Higher drinking frequency corresponds to lower synaptic density in people with alcohol use disorder
Zakiniaeiz, Y., Raval, N. R., Riordan, W., Nabulsi, N., Huang, Y. H., Pittman, B. P., Matuskey, D., Angarita, G. A., Robin, B., McKee, S. A., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199989 · Cited by 4
“Regional BP ND values were calculated using the simplified reference tissue model 2 with a group-specific fixed k 2 ′ to account for inherent group differences and the centrum semiovale as a reference region, as previously described (23) (see Supplemental Methods for more details).”
Self-citationFesharaki‐Zadeh, A., Çayır, S., Ibrahim, W., Yang, Y., Gallezot, J., Naganawa, M., Wu, Y., Toyonaga, T., Sadabad, F. E., O’Dell, R. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71283 · Cited by 4
Self-citationLaroy, M., Laere, K. V., Vandenbulcke, M., Emsell, L., & Bouckaert, F. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001094 · Cited by 4
Lien, C.-H., Casteele, T. V., Laroy, M., Cauwenberge, M. G. A. V., Peeters, R. R., Sunaert, S. G., Laere, K. V., Dupont, P. J., Bouckaert, F., Emsell, L., et al. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf028 · Cited by 4
Trenité, D. G. A. K.-N., & Löscher, W. (2025) · Epilepsia · doi:10.1111/epi.18468 · Cited by 4
“A positron emission tomography (PET) ligand for SV2A has been examined as a marker of synaptic density in both baboons and humans, 50 but, to our knowledge, it is not known whether SV2A binding of this ligand is altered in photosensitive baboons or patients (see also 51 ).”
Update on Molecular Imaging in Epilepsy
Vengadesan, K., Phulia, A., & Kumar, R. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.05.007 · Cited by 4
Chia, P. H. J., Toyonaga, T., Tong, J., Le, H., Dias, M., Boyle, A. J., Raymond, R., Longbrake, E. E., Huang, Y. H., Carson, R. E., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2517709123 · Cited by 4
Self-citationJiang, Z., Cheng, X., Chen, H., Zheng, W., Sun, Y., Yu, Z., Yang, T., Zhang, L., Fan, D., Yang, Z., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00062 · Cited by 5
The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsy
Marstrand-Joergensen, M. R., Dam, V. H., Vinter, K., Ip, C.-T., Jensen, K. H. R., Jørgensen, M. B., Hoei‐Hansen, C. E., Ozenne, B., Fisher, P. M., Knudsen, G. M., et al. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101136 · Cited by 5
“The radioligand [ 11 C]-UCB-J binds to SV2A (Finnema et al., 2016), and PET [ 11 C]-UCB-J studies have provided evidence of decreased synaptic density in epilepsy patients (Finnema et al., 2016, 2020).”
InfluentialBini, J., Lattin, C. R., Toyonaga, T., Finnema, S. J., & Carson, R. E. (2021) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2021.3088606 · Cited by 5
Self-citationPazarlar, B. A., Madsen, C. A., Oyar, E. Ö., Eğilmez, C. B., & Mikkelsen, J. D. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.106926 · Cited by 4
Identification of pre-synaptic density networks using [11C]UCB-J PET imaging and ICA in mice
Akkermans, J., Zajicek, F., Miranda, A., Adhikari, M. H., & Bertoglio, D. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119771 · Cited by 4
Positron Emission Tomography (PET) Imaging Biomarkers in Huntington’s Disease
Everix, L., Staelens, S. G., & Bertoglio, D. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_6 · Cited by 4
Mikkelsen, J. D., Aripaka, S. S., Eğilmez, C. B., & Pazarlar, B. A. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105717 · Cited by 4
“…in the hippocampus is accompanied by reduction in SV2A, a presynaptic protein localized in the vesicular membrane and shown to be reduced in several animal models of epilepsy and in human epilepsy brains (Carson et al., 2022; Finnema et al., 2016; Mikkelsen et al., 2022; Pazarlar et al., 2022a,b).”
BackgroundSynaptic density directly visualized in human brains
Morris, A. W. J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.116 · Cited by 4
The transcriptional and cellular landscape of cognitive resilience to Alzheimer’s disease
Khera, N., Raju, R. M., & Lipton, S. A. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1665802 · Cited by 3
“…(MMSE) and the Montreal Cognitive Assessment (MoCA) or biomarkers of synaptic loss, such as positron emission tomography (PET) scans for the presynaptic marker SV2A, which has been reported to reflect synapse number (Arevalo-Rodriguez et al., 2021; Davis et al., 2021; Finnema et al., 2016).”
Preclinical validation and kinetic modelling of the SV2A PET ligand [ 18 F]UCB-J in mice
Everix, L., Elvas, F., Miranda, A., Khetarpal, V. K., Liu, L., Bard, J., Staelens, S. G., & Bertoglio, D. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241304923 · Cited by 4
Walsh, M. J. M., Gibson, K., Gray, R., McNeal, M., Lynch, L. S., Kang, M., Brierley, J. D., Bondy, E., Dichter, G. S., & Schiller, C. E. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251348865 · Cited by 5
“–110 In humans, reproductive transition effects on structural brain plasticity have been confirmed using MRI, 5,111 but PET imaging of synaptic density 112 offers a way to directly study synaptic changes in future research.”
Xiao, L., Wang, J., Chen, B., Yang, J., Wu, F., Zhou, C., Zhang, Y., Yang, Z., Liu, D., Tian, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202508161 · Cited by 5
The “five-star matrix” for patient-centric drug discovery and development in neuroscience
Pähler, A., O’Connor, E. C., Binch, H., Dudal, S., Gobbi, L. B., Lübbers, T., Olivares‐Morales, A., Sarmiento, R. M. R., Grether, U., Ståhl, M., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.004 · Cited by 3
Anatomical white matter tracts span the cortical hierarchy to support cognitive diversity
Bagautdinova, J., Shafiei, G., Luo, A. C., Pecsok, M. K., Salo, T., Alexander‐Bloch, A. F., Bassett, D. S., Gardner, M., Gur, R. E., Gur, R. C., et al. (2026) · Nature Human Behaviour · doi:10.1038/s41562-026-02559-5 · Cited by 3
Khattar, N., Matuskey, D., Gallezot, J., Naganawa, M., Holmes, S. E., Sadabad, F. E., Mayeli, M., Esterlis, I., van Dyck, C. H., Mecca, A. P., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261441071 · Cited by 3
“5,13,35 38 Although the small volume (2 mL in template space, 2 mL in subject space) and deep location renders the previously proposed CS2mL ROI relatively invulnerable to GM spill-in effects that would bias DVR values, due to the smaller proportion of voxels at the boundary of WM and GM, it also…”
Self-citationVanderlinden, G., Carron, C. P., Opstal, J. V., Cohilis, M., Vandenberghe, W., Koole, M. J. B., & Laere, K. V. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261454164 · Cited by 3
Cao, L., Wang, Z., Yuan, Z., & Luo, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-07404-x · Cited by 4
Pazarlar, B. A., Eğilmez, C. B., Oyar, E. Ö., & Mikkelsen, J. D. (2025) · Synapse · doi:10.1002/syn.70018 · Cited by 3
“This raises concerns about the reliability of SV2A binding as a consistent marker of synapse density, as originally proposed (Finnema et al. 2016; Finnema et al. 2020).”
Widespread synaptic density loss in schizophrenia follows molecular and network architecture
Chopra, S., Worhunsky, P. D., Naganawa, M., Zhang, X.-H., Segal, A., Labache, L., Orchard, E. R., Cropley, V., Wood, S. J., Angarita, G. A., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03717-x · Cited by 5
Self-citationState of the art of radiochemistry for 11C and 18F PET tracers
Ważyńska, M. A., Haveman, L. Y. F., Windhorst, A. D., Elsinga, P. H., & Vugts, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00007-7 · Cited by 3
d’Orchymont, F. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/uswk7545 · Cited by 3
Millevert, C., Vidas-Guscic, N., Adhikari, M. H., Miranda, A., Vanherp, L., Jonckers, E., Joye, P., Audekerke, J. V., Spilbeeck, I. V., Verhoye, M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105720 · Cited by 3
“25 Synaptic density and plasticity are critical determinants of neural circuit function and, by extension, cognitive processes.”
Meyer, S. D., Alali, S., Laroy, M., Casteele, T. V., Cauwenberge, M. G. A. V., Goossens, J., Rocker, C. D., Vanbrabant, J., Vanmechelen, E., den Stock, J. V., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf207 · Cited by 3
“18,19 A recent neuro-pathological study reported moderate to strong correlations between SV2A and synaptophysin densities across multiple cortical brain regions and neurodegenerative disorders (i.e. Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal lobar degeneration with TAR…”
Duvoor, C., Dendi, V. S., Marco, A., Shekhawat, N. S., Chada, A., Ravilla, R., Musham, C. K., Mirza, W., & Chaudhury, A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00053 · Cited by 4
“GENERAL COMMENTARY published: 02 February 2017 doi: 10.3389/fphys.2017.00053 Frontiers in Physiology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 53 Edited by: Ghanshyam Upadhyay,”
BackgroundInfluentialRollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2024) · eLife · doi:10.7554/elife.99473 · Cited by 3
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
Marstrand-Joergensen, M. R., Laurell, G. L., Herrmann, S., Nasser, A., Johansen, A., Lund, A., Andersen, T. L., Knudsen, G. M., & Pinborg, L. H. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06759-x · Cited by 2
“SV2A is located in vesicles of the presynaptic nerve terminal [ 10 ] and is recognized as a synaptic marker [ 11].”
BackgroundMethodInfluentialAsch, R., Naganawa, M., Moisieienko, K., Weed, M., Kapinos, M., Zheng, M., Hillmer, A. T., Carson, R. E., Pietrzak, R. H., & Esterlis, I. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01200-2 · Cited by 2
Self-citationEverix, L., Zajicek, F., Eetveldt, A. V., Liu, L., Bard, J., Staelens, S. G., & Bertoglio, D. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103800 · Cited by 2
“A common method to evaluate synaptic deficits is to quantify the synaptic vesicle protein 2A (SV2A), a widely recognized surrogate for synaptic density (Finnema et al., 2016; Carson et al., 2022).”
Ghosh, S., Shukla, G., & Kumar, P. (2025) · Materials Today Communications · doi:10.1016/j.mtcomm.2025.113115 · Cited by 2
Jager, J. E. D., van der Weijden-Germann, M., van Dellen, E., de Vries, E. F. J., Sommer, I. E., & Nuninga, J. O. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.11.008 · Cited by 5
Asch, R., Fan, S., Cool, R., Boster, S., DellaGioia, N., Naganawa, M., Nabulsi, N., Lacadie, C., Pietrzak, R. H., & Esterlis, I. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.018 · Cited by 2
Self-citationEichler, A., Kruse, P., Schob, C., & Lenz, M. (2025) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2025.1724377 · Cited by 4
“In recent years, in vivo PET imaging of synaptic density has become feasible using a tracer targeting synaptic vesicle glycoprotein 2A [SV2A; (Finnema et al., 2016)].”
Social determinants of brain structure and cognition
Mayeli, M., & Matuskey, D. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119045 · Cited by 2
Self-citation
Metadata
- Authors
- Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D. D., Mercier, J., Hannestad, J., Huang, Y., & Carson, R. E.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Finnema, Sjoerd J.
- Hannestad, Jonas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-07-20
- Volume
- 8
- Issue
- 348
- Pages
- 348ra96-348ra96
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2503767557
- Cited by
- 575
- References
- 59
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 81 · 2023: 54 · 2022: 92 · 2021: 67 · 2020: 54 · 2019: 43 · 2018: 23 · 2017: 31 · 2016: 6
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swebilius Foundation
- UCB Pharma
- Swedish Research Council
- National Center for Advancing Translational Science (UL1 TR000142)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- synaptic density, SV2A, positron emission tomography, presynaptic terminals, synaptophysin, temporal lobe epilepsy, synaptic loss, Alzheimer's disease, neuroimaging
- MeSH terms
- Adult, Aged, Brain, Epilepsy, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Synapses, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.